Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Neuroendocrine Tumors Global Market 2016 Prospectus, Examination and Forecast to 2021

Thursday, October 13, 2016 21:16
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

 

Get Sample Report @ https://www.wiseguyreports.com/sample-request/535878-neuroendocrine-tumors-pipeline-review-h1-2016

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors

- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects

- The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=535878

 

Table of Contents

Table of Contents 2

Introduction 5

Neuroendocrine Tumors Overview 6

Therapeutics Development 7

Neuroendocrine Tumors – Therapeutics under Development by Companies 9

Neuroendocrine Tumors – Therapeutics under Investigation by Universities/Institutes 11

Neuroendocrine Tumors – Pipeline Products Glance 12

Neuroendocrine Tumors – Products under Development by Companies 15

Neuroendocrine Tumors – Products under Investigation by Universities/Institutes 18

Neuroendocrine Tumors – Companies Involved in Therapeutics Development 19

Neuroendocrine Tumors – Therapeutics Assessment 54

Drug Profiles 66

Neuroendocrine Tumors – Recent Pipeline Updates 186

Neuroendocrine Tumors – Dormant Projects 288

Neuroendocrine Tumors – Discontinued Products 289

Neuroendocrine Tumors – Product Development Milestones 290

Appendix 297

 

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H1 2016 13

Number of Products under Development for Neuroendocrine Tumors – Comparative Analysis, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Number of Products under Development by Companies, H1 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Comparative Analysis by Late Stage Development, H1 2016 18

Comparative Analysis by Clinical Stage Development, H1 2016 19

Comparative Analysis by Early Stage Development, H1 2016 20

Products under Development by Companies, H1 2016 21

…Continued

 

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H1 2016 13

Number of Products under Development for Neuroendocrine Tumors – Comparative Analysis, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Comparative Analysis by Late Stage Development, H1 2016 18

Comparative Analysis by Clinical Stage Development, H1 2016 19

Comparative Analysis by Early Stage Products, H1 2016 20

Assessment by Monotherapy Products, H1 2016 60

Number of Products by Top 10 Targets, H1 2016 61

Number of Products by Stage and Top 10 Targets, H1 2016 61

…Continued

 

Access Report @ https://www.wiseguyreports.com/reports/535878-neuroendocrine-tumors-pipeline-review-h1-2016

 

Reach Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

 

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.